Furthermore, patients with activating mutations in NRAS have a poorer prognosis, are refractory to BRAF inhibition, and exhibit a greater incidence of brain metastases than patients with either BRAF-mutant or BRAF/NRAS wild-type melanoma (1, 13). This evidence concerns the gene BRAF and melanoma.